慢性胃炎病人应用雷贝拉唑治疗的症状转归情况评价  

Evaluation of Symptom Outcome of Chronic Gastritis Patients Treated with Rabeprazole

作　　者：罗盛丰 LUO Shengfeng(Gastroenterology Department,Shenzhen City Futian District The Second People's Hospital,Shenzhen,Guangdong 518000)

机构地区：[1]广东省深圳市福田区第二人民医院消化内科,广东深圳518000

出　　处：《智慧健康》2023年第3期158-161,共4页Smart Healthcare

摘　　要：目的评价慢性胃炎病人应用雷贝拉唑治疗的症状转归情况。方法选取2021年1月-2022年1月本院收治的慢性胃炎患者78例为研究样本。采取随机抽样分组法划分组别,即单药、联用二组,39例/组,治疗方案依次为替普瑞酮单一药物治疗、替普瑞酮+雷贝拉唑两种药物联合治疗。评析指标:两组治疗后的症状改善时间、胃动力指标、治疗有效性、药物副作用发生率。结果在对慢性胃炎患者进行治疗后,联用组的症状改善时间短于单药组(P<0.05);联用组的胃动力指标低于单药组(P<0.05);联用组的治疗有效性高于单药组(P<0.05);联用组的药物副作用发生率与单药组相比无明显差异性(P>0.05)。结论在对慢性胃炎患者进行治疗时,应用替普瑞酮+雷贝拉唑治疗能够缩短症状改善时间,改善胃动力情况,提高治疗有效性,且药物副作用发生率不高,推荐使用。Objective To evaluate symptom outcome of patients with chronic gastritis treated with rabeprazole.Methods The paper chose 78 patients with chronic gastritis admitted to our hospital from January 2021 to January 2022 as study samples,and divided them into two groups with randomized sampling and grouping method,namely,single drug group and combined drug group,39 cases/group.Treatment plan was followed by single drug treatment of teprenone and combined treatment of teprenone+rabeprazole.Evaluation indicators:time of symptom improvement,gastric motility index,treatment effect,incidence of side effect of drugs between two groups after treatment.Results After treatment of chronic gastritis patients,improvement time of symptoms in combination group was shorter than single drug group(P<0.05);gastric motility index of participants in combination group was lower than single drug group(P<0.05).Treatment effect of combined group was higher than single drug group(P<0.05);there was no significant difference in incidence of side effect between combination group and single drug group(P>0.05).Conclusion In treatment of chronic gastritis patients,teprenone+rabeprazole can shorten time of symptom improvement,improve gastric motility,and treatment effect,with low incidence of side effect,which is recommended for application.

关 键 词：慢性胃炎 雷贝拉唑 替普瑞酮 症状改善时间 胃动力指标 治疗有效性 药物副作用发生率 

分 类 号：R573.3[医药卫生—消化系统]